VT-11CR for Liver Cancer

Our primary strategy with VT-11CR is aimed at patients with advance hepatocellular carcinoma (“HCC”) that are receiving sorafenib. This type of liver cancer represents approximately 40% of all liver cancer cases in the US We are initially focused on the treatment of Child-Pugh A and B patients whom have progressed after receiving local-regional therapy.

Despite advances in the diagnosis and treatment of these patients, most will progress on sorafenib therapy with an expected survival of less than one year. We believe that our strategy to damp tumor-promoting inflammation, restore immune surveillance and improve treatment tolerance with VT-11CR may significantly improve outcomes for HCC patients.